Immunotherapy approaches for hematological cancers - ScienceDirect
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Novità nella terapia dell'amiloidosi AL | Negli ultimi anni, i...
ASH 2018: DETER - Dara+Rev+Dex for High-Risk Smoldering Myeloma - YouTube
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies | Blood Cancer Journal
Cancers | Free Full-Text | Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives
Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
TRANSCRIPT
ASH 2018: DETER - Dara+Rev+Dex for High-Risk Smoldering Myeloma - YouTube
COMMISSION DE LA TRANSPARENCE
ASH 2018: Adding Daratumumab to Velcade/Revlimid/Dex Effective for Newly Diagnosed Multiple Myeloma - HealthTree for Multiple Myeloma
My key take-aways – ASH 2016 Blogs
ASH 2018: DETER - Dara+Rev+Dex for High-Risk Smoldering Myeloma - YouTube
Bim downregulation by activation of NF-κB p65, Akt, and ERK1/2 is associated with adriamycin and dexamethasone resistance in multiple myeloma cells | Clinical and Experimental Medicine
Effect of 10 nM dexamathasone (DEX) and DEX 0.5 mM 8-bromo-cAMP (cAMP)... | Download Scientific Diagram
Key Trial Data Supporting the Use of Selinexor in Patients with R/R MM
2-Minute Drill: Experts Highlight Latest Blood Cancer Research Following 2022 ASH
Studypages - Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Impact of the Phase 3 APOLLO Trial Recent Findings
Pharmaceuticals | Free Full-Text | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
EHA 2021: Transplant Ineligible Myeloma Patients Do Better With the Addition of Daratumumab - HealthTree for Multiple Myeloma
How I treat high-risk multiple myeloma - ScienceDirect
